Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (13377)	10/7/2004 11:04:58 AM
From: Biomaven	Read Replies (1) \| Respond to of 52153

Part of the issue is that questions have been raised about Vioxx's safety issues for quite some time now. One of the early studies showed it doing quite a bit worse than Naprosyn - MRK's (not altogether unreasonable) response to that was that Naprosyn was having a good cardiac effect, somewhat like aspirin, and so Vioxx wasn't actually doing harm, simply not doing good. But that position was steadily eroded even before the latest study, particularly with the very recent Kaiser observational study. But this does hurt the drug industry as a whole and will undoubtedly serve to make the FDA more cautious. All the cox-2 inhibitors will now be under something of a cloud. Wolfe's group never like the cox-2 drugs, and to some extent he has been vindicated. Peter